Radiation plus chemoimmunotherapy for gastroesophageal junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenocarcinoma cancer at the junction of the stomach and esophagus that has not spread to distant organs.
- You have not had any prior treatment for this cancer.
- You are 18 years or older and able to care for yourself (ECOG 0 or 1).
- Your heart, liver, kidneys, and blood counts are working well enough based on recent tests.
- You do not have an active autoimmune disease, uncontrolled infection, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This trial combines an experimental immunotherapy drug with standard chemotherapy before and after surgery for patients with a specific type of stomach-esophagus cancer. The goal is to see if this combination improves outcomes, including shrinking the tumor to make surgery more effective.
This trial tests a new drug (pucotenlimab), which helps your immune system fight cancer, combined with chemotherapy, given before and after surgery for gastroesophageal junction cancer. The goal is to see if this combination can shrink the tumor and improve outcomes for patients with this type of cancer.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.